Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

2014 ASH Annual Meeting

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.

Multiple Myeloma

Sagar Lonial, MD

Sagar Lonial, MD, on the Phase III ASPIRE Trial

Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 79, “Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma: Interim Results From ASPIRE, a Randomized, Open-Label, Multicenter Phase III Study,” presented by A. Keith Stewart, MD.

Leukemia

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, discuss the diagnosis and genetics of ALL, differences in treating younger and older patients, and the latest data on the use of tyrosine kinase inhibitors, monoclonal antibodies, and CAR T cells.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.

Leukemia

Linda J. Burns, MD

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380, “T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD.

Time: 1:26

May

Today In Oncology

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Related Videos

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

Sagar Lonial, MD, on the Phase III ASPIRE Trial

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

Nearly Half of Black Patients With Metastatic Breast Cancer Report Not Being Informed About Clinical Trials

Race/Ethnicity and Poverty Are Associated With Worse Outcomes Among Children With High-Risk Neuroblastoma

Study Finds State Public Welfare Spending Was Associated With Improved 5-Year Overall Survival in Black Patients With Cancer

Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic, but Varied by Race, Socioeconomic Status, and Other Factors

Watch-and-Wait Strategy for Organ Preservation in Patients Receiving Total Neoadjuvant Therapy for Rectal Adenocarcinoma